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$EVWUDFW Norovirus infection and illness are increasingly used as end-points in sewage-related health
risk assessments, especially as data from clinical trials outbreak studies have recently become
available. The authors of a very recent clinical trial have inferred that the human median infectious
dose is higher than previous estimates and similar to that of other RNA viruses. This finding has the
potential to cause a revision of previous risk assessments. However, in reaching this conclusion, the
potential role of aggregation of these viruses seems not to have been accounted for, although it was
accounted for in an earlier trial. In fitting (hypergeometric) dose-response curves to data from
Norovirus clinical trials, the potential for the laboratory-stored stock of this non-culturable virus to have
become aggregated onto storage matrix substances, as observed in a clinical trial, must be
addressed. That is because standard dilution series calculations for doses are based on the
assumption of uniform mixing of disaggregated particles. "Low" doses derived in this manner may
therefore actually be "No" doses and lack of an infection response in trial participants at such doses
may reflect absence of the virus in inocula, rather than reflecting its infectivity status. The possible
consequences of including aggregation in a re-analysis of such data is explored. Research into the
potential for sewage treatment processes to promote aggregation would be of benefit to sewagerelated QMRAs.
.H\ZRUGVNorovirus; dose-response; aggregation; clinical trial; outbreak
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The aetiological agent in diluted sewage-contaminated water causing excess illnesses among
swimmers and other recreational water users is increasingly identified as Norovirus (e.g., Sinclair
2009). Until recently, information on dose-response characteristics of this pathogen has been lacking.
But in recent years three studies have emerged that have shed light on this gap—so much so that
Norovirus infection and illness impacts have gained an increasing role in quantitative microbial risk
assessments (QMRA) (e.g., Soller et al. 2010). These studies are:
1. Analysis of Norwalk (genogroup GI.1) virus clinical trial data, reported by Teunis et al. (2008);
2. Outbreak studies for a range of Noroviruses (GI, GI.1, GI.4, GII, GII.4, GII.8, GII.9) for consumers
of raw oysters in southern France (Thebault et al. 2013);
3. An independent Norwalk virus (GI.1) clinical trial study, reported by Atmar et al. 2013.
We will focus herein on differences between infection (cf. illness) dose-response for Norwalk (GI.1)
viruses between these three studies. There are also differences in predicted illness responses, but to
some extent at least, they are driven by differences in infection dose-response. We also focus only on
the "susceptible" individuals in the trials and outbreak study (~70% in the first study). For studies 1
and 2 these are defined as "Se+ Virus binding to intestinal epithelial cells depends on a secretor
phenotype: non-secretors (Se–) lack the receptor and so the virus cannot bind to cause infection. In
the third study two susceptible groups were defined: (i) secretor-positive blood group O or A; (ii) all
secretor-positive persons. For consistency we will use only the latter. In this way we can assume that
the distribution of susceptible individuals in the three studies are made a similar as possible, though
there is insufficient information to further quantify the relative consistency and ages of susceptible
individuals between the three studies.
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A key feature of this analysis is that the aggregation of viruses in doses given to individuals in a
clinical trial must be accounted for when calibrating a suitable dose-response curve. However, when
applying the dose-response curves to non-aggregated virions the aggregation parameter is set to
nought ZKLOVWWKHRWKHUSDUDPHWHUVUHPDLQXQFKDQJHG.



&203$5,1*7+(7(81,6$1'7+(%$8/7678',(6

As shown in Figure 1, the infection dose-response for studies 1 and 2 are rather similar, rising steeply
at the origin and flattening out before the median Human Infectious Dose (HID50) is reached: 26
virions for the clinical trial and 7 virions for the outbreak study. The outbreak study analysis indicates
the stronger infectivity, particularly at higher doses (higher than commonly predicted for sewagerelated QMRA exercises).
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0HDQGRVH JF
)LJXUH. Non-aggregation infection dose-response curves from Teunis et al. (2008) and Thebault et
al. (2013). Both curves have been calculated using the formula Pr(infection | G) = 1 – 1F1(Į, Į + ȕ, –G),
where 1F1 is the Kummer confluent hypergeometric function, Gis the mean dose received by a group
of trial participants (in genome copies) and Į and ȕ are shape and location parameters. The Teunis
(Į, ȕ) set is taken from their Table III with aggregation parameter (D) set to zero. The Thebault (Į, ȕ)
set was obtained by fitting to their published median curve, using the "FindFit" procedure in
Mathematica®. (Note that the first four doses reported in Teunis et al. 2008 are all a factor of
10 too high—SHUVFRPP. Dr. Peter Teunis, RIVM.)


 $FFRXQWLQJIRUDJJUHJDWLRQ
At first sight the continuous curve shown in Figure 1 is a poor fit with the low dose data. The
explanation for that is provided by the observation in Teunis et al. (2008) that the first part of their trial
(8fIIa) used laboratory-stored virions that had become strongly aggregated, as judged by electron
microscopy (the second part, 8fIIb, used fresh non-aggregated inocula).1 Accounting for that
aggregation gives rise to a different functional form of the ingestion dose-response equation, the
Gauss hypergeometric function: Pr(infection | G) = 1 – 2F1[Į, G(1–D)/D, Į + ȕ, –D/(1–D)], results for
which are shown in Figure 2. Note that the value of D in that Figure (D = 0.9997) corresponds to a


1
Electron microscopy alone may not be sufficient to fully characterise aggregation, because samples must first be stained and
dried (SHUVFRPP. Dr Jeremie Langlet, ESR, Porirua, New Zealand).
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mean aggregate size of ȝD § 400, using the formula presented in Supplementary Information for the
Teunis et al. (2008) paper: ȝD = –D[(1–D)ln(1–D)]–1 virions.
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0HDQGRVH JF
)LJXUH. Accounting for virus aggregation in the clinical trial data analysed by Teunis et al. (2008).

Inspection of Figure 2 shows that the fit of this equation (the dashed line) with the low dose data is
close, and that the HID50 is now 1058 virions. Consequently, if a QMRA were to be based on fresh
non-aggregated virions (such as the 8fIIb data) the solid curve in Figure 2 (or Figure 1) is the
appropriate choice—even though the dashed curve in Figure 2 offers the best fit. The reason for this
at-first-puzzling feature lies in the discrete nature of these virions: Standard dilution series calculations
for doses are based on the assumption of uniform mixing of disaggregated particles. Effectively that
assumes that there will always be VRPHviruses present in diluted inocula. However, for aggregated
conditions "Low" doses derived in this manner will usually actually be "No" doses and lack of an
infection response in trial participants at such doses may reflect absence of the virus for aggregated
inocula, rather than reflecting its infectivity status. This possibility is strongly suggested by the two
lowest doses in Figures 1 and 2, for which the infection response is completely absent.
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This study reports significantly lower infectivity than studies 1 and 2, with a HID50 of about 2800 for the
Se+ individuals, based on a logistic regression approach. The authors concluded that this result is
similar to that of other RNA viruses. While acknowledging the examination of aggregation made by
Teunis et al. (2008), this issue was not addressed in the paper. However, a supporting publication
(Atmar et al. 2011) notes that "The study vaccine contained … a mucoadhesive agent…", which is
suggestive of some aggregation.
Figure 3 displays three hypergeometric functions fitted to this study's data (such fits to hypergeometric
functions were not reported by Atmar et al. 2013).
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0HDQGRVH JH
)LJXUH. Accounting for virus aggregation in the clinical trial data analysed by Atmar et al. (2013).
Doses in genome equivalents (ge) are defined as 400 times the trial's RT-PCR units. Note that the
values of Į, ȕ and D in this Figure refer to doses measured in the trial's RT-PCR units, not to the ge
values (the "FindFit" procedure in Mathematica® was not convergent for ge units).
ge units are plotted here to facilitate comparison with Figures 1 and 2.
The first (solid line) is a best fit, ignoring any aggregation, giving rise to a HID50 of 1624. The second
line (short dashes) fits a Gauss hypergeometric function with an arbitrary value of the aggregation
parameter set to 0.92 (the Mathematica® "FindFit" procedure failed to converge at higher values of D,
presumably because the sample size is small). This value of the aggregation parameter corresponds
to a mean aggregate size of about 4.5 virions.This gives rise to a slightly lower HID50 (1610). The third
line (long dashes) resets the aggregation parameter (D) to zero, but retains the second line's (Į, ȕ)
set. The motivation for doing so is the same as for Figure 2: When analyzing a clinical trial with
aggregated virions, that aggregation must be accounted for, but when applying the dose-response
parameters to non-aggregated virions the parameter Dis irrelevant. As expected, this resetting (of D),
shifts the dose-response curve to the left; its HID50 is 355. Had the second curve used a higher value
of Dan even greater reduction in apparent infectiousness would have arisen.
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The strident difference between the Norovirus HID50 values derived from data reported for the two
independent clinical trials may be considerably lessened were the role of virus aggregation in the
most recent trial quantified and accounted for.
In conducting QMRA for Noroviruses, the possibility of aggregation of the viruses needs to be taken
into account; there can be substantial changes in indicated infectivity if this is not done. While fresh
sewage can be expected to be not aggregated, we lack data and information on the degree of
aggregation that may be accumulated during wastewater treatment processes (e.g., activated sludge
processes deliberately seek some aggregation). That lack poses a challenge for risk analysts and
infrastructure operators. Research to examine this question in some detail would appear to be fruitful.
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Jeff Soller, Peter Teunis, Mary Schoen, Nicole van Abel, Rebecca Stott, Beverley Horn, Stefan
Wuertz and Scott Meschke have made useful comments. This work was funded by my employer
(NIWA) via a research programme on QMRA associated with raw feral shellfish consumption.

5()(5(1&(6
Atmar, R.L., Opekun, A.R., Gilger, M.A., Estes, M.K., Crawford, S.E., Neill, F.H., Ramani, S., Hill, H.,
Ferreira, J., Graham, D.Y., 2013. Determination of the human infectious dose-50% for Norwalk
virus. J. Infect Dis. doi: 10.1093/infdis/jit620.
Atmar, R.L., Bernstein, D.I., Harro, C.D., Al-Ibrahim, M.S., Chen, W.H., Ferreira, J., Estes, M.K.,
Graham, D.Y., Opekun, A.R., Richardson, C., Mendelman, P.M., 2011. Norovirus vaccine against
experimental human Norwalk virus illness. New Eng. J. Med. 365, 2178–2187.
Sinclair, R.G., Jones, E.L., Gerba, C.P., 2009. Viruses in recreational water-borne disease outbreaks:
a review. J. Appl. Microbiol. 107 (6), 1769–1780.
Soller, J.A., Bartrand, T., Ashbolt, N.J., Ravenscroft, J., Wade, T.J., 2010. Estimating the primary
etiologic agents in recreational freshwaters impacted by human sources of fecal contamination.
Water Res. 44 (16), 4736–4747.
Teunis, P.F.M., Moe, C.L., Liu, P., Miller, S.E., Lindesmith, L., Baric, R.S., Le Pendu, J., Calderon, R.,
2008. Norwalk virus: How infectious is it? J. Med. Virol. 80, 1468–1476 (and Supplementary
Information).
Thebault, A., Teunis, P.F., Le Pendu, J., Le Guyader, F.S., Denis, J.B., 2013. Infectivity of GI and GII
noroviruses established from oyster related outbreaks. Epidemics 5, 98–110.

Page 1512

